Zymeworks Inc has a consensus price target of $19.71, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, HC Wainwright & Co., and HC Wainwright & Co. on March 12, 2024, March 11, 2024, and August 15, 2023. With an average price target of $10.67 between Wells Fargo, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 24.61% upside for Zymeworks Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/12/2024 | ZYME | Buy Now | Zymeworks | $8.56 | 63.55% | Wells Fargo | Derek Archila | $12 → $14 | Maintains | Overweight | Get Alert |
03/11/2024 | ZYME | Buy Now | Zymeworks | $8.56 | 16.82% | HC Wainwright & Co. | Robert Burns | $8 → $10 | Maintains | Neutral | Get Alert |
08/15/2023 | ZYME | Buy Now | Zymeworks | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | → $8 | Reiterates | Neutral → Neutral | Get Alert |
06/06/2023 | ZYME | Buy Now | Zymeworks | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | → $8 | Reiterates | Neutral → Neutral | Get Alert |
05/18/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 110.28% | Citigroup | Yigal Nochomovitz | $17 → $18 | Maintains | Buy | Get Alert |
05/09/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 121.96% | Stifel | Stephen Willey | $18 → $19 | Maintains | Buy | Get Alert |
03/31/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 5.14% | JP Morgan | Brian Cheng | $8 → $9 | Maintains | Neutral | Get Alert |
03/21/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 40.19% | Wells Fargo | Derek Archila | → $12 | Assumes | → Overweight | Get Alert |
03/21/2023 | ZYME | Buy Now | Zymeworks | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | → $8 | Reiterates | → Neutral | Get Alert |
03/10/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 98.6% | Citigroup | Yigal Nochomovitz | $21 → $17 | Maintains | Buy | Get Alert |
03/08/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 86.92% | Guggenheim | Charles Zhou | → $16 | Reiterates | → Buy | Get Alert |
01/24/2023 | ZYME | Buy Now | Zymeworks | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | → $8 | Reiterates | → Neutral | Get Alert |
01/20/2023 | ZYME | Buy Now | Zymeworks | $8.56 | 16.82% | SVB Leerink | Andrew Berens | $8 → $10 | Maintains | Market Perform | Get Alert |
01/04/2023 | ZYME | Buy Now | Zymeworks BC | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | $10 → $8 | Maintains | Neutral | Get Alert |
12/22/2022 | ZYME | Buy Now | Zymeworks BC | $8.56 | 5.14% | Barclays | Gena Wang | $7 → $9 | Maintains | Equal-Weight | Get Alert |
12/20/2022 | ZYME | Buy Now | Zymeworks BC | $8.56 | 28.5% | Jefferies | Akash Tewari | $7.7 → $11 | Upgrade | Hold → Buy | Get Alert |
11/21/2022 | ZYME | Buy Now | Zymeworks BC | $8.56 | 16.82% | HC Wainwright & Co. | Robert Burns | $8 → $10 | Maintains | Neutral | Get Alert |
11/01/2022 | ZYME | Buy Now | Zymeworks BC | $8.56 | -6.54% | HC Wainwright & Co. | Robert Burns | $40 → $8 | Downgrade | Buy → Neutral | Get Alert |
10/24/2022 | ZYME | Buy Now | Zymeworks BC | $8.56 | 110.28% | Stifel | Stephen Willey | $21 → $18 | Maintains | Buy | Get Alert |
The latest price target for Zymeworks (NASDAQ: ZYME) was reported by Wells Fargo on March 12, 2024. The analyst firm set a price target for $14.00 expecting ZYME to rise to within 12 months (a possible 63.55% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Zymeworks (NASDAQ: ZYME) was provided by Wells Fargo, and Zymeworks maintained their overweight rating.
The last upgrade for Zymeworks Inc happened on December 20, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Zymeworks Inc.
The last downgrade for Zymeworks Inc happened on November 1, 2022 when HC Wainwright & Co. changed their price target from $40 to $8 for Zymeworks Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on March 12, 2024 so you should expect the next rating to be made available sometime around March 12, 2025.
While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a maintained with a price target of $12.00 to $14.00. The current price Zymeworks (ZYME) is trading at is $8.56, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.